Pattern of timing adherence could guide recommendations for personalized intake schedules.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4251372)

Published in J Pers Med on November 28, 2012

Authors

Philipp Walter1, Isabelle Arnet2, Michel Romanens3, Dimitrios A Tsakiris4, Kurt E Hersberger5

Author Affiliations

1: Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Pharmazentrum, Klingelbergstrasse 50, CH-4056 Basel, Switzerland. philipp.walter@unibas.ch.
2: Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Pharmazentrum, Klingelbergstrasse 50, CH-4056 Basel, Switzerland. isabelle.arnet@unibas.ch.
3: Vascular Risk Foundation VARIFO, Ziegelfeldstrasse 1, CH-4600 Olten, Switzerland. info@kardiolab.ch.
4: Diagnostic Hematology, University Hospital of Basel, Petersgraben 4, CH-4031 Basel, Switzerland. TsakirisD@uhbs.ch.
5: Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Pharmazentrum, Klingelbergstrasse 50, CH-4056 Basel, Switzerland. kurt.hersberger@unibas.ch.

Associated clinical trials:

Aspirin and Clopidogrel Resistance Study | NCT01039480

Articles cited by this

Adherence to medication. N Engl J Med (2005) 39.77

Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care (2004) 12.32

Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) (2008) 12.08

Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res (1999) 9.85

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (2000) 8.86

How often is medication taken as prescribed? A novel assessment technique. JAMA (1989) 5.98

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med (2000) 3.93

Bias. J Epidemiol Community Health (2004) 3.85

Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ (2008) 3.24

Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med (2005) 3.19

Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol (1996) 2.84

Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens (2001) 1.80

Comparing compliance patterns between randomized treatments. Control Clin Trials (1997) 1.25

Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther (2010) 1.03

Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med (1998) 1.02

Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration. Ann Pharmacother (2007) 0.91